TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00979745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 9 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One 16mg subcutaneous implant every 2 months for 9 months.
Study: NCT03912818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT02870751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TW11681 or TW10722
Study: NCT04778449

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical charts are reviewed

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01678898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102
Study: NCT03489837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levotuss
Description: oral taken

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levotuss
Description: oral taken
Study: NCT00352391

Intervention type: OTHER
Intervention: Assessments
Description: At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
Study: NCT03600519

Intervention type: DEVICE
Intervention: NOTAL OCT V2.5
Description: AMD Patients
Study: NCT02897999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03912818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT02897999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03912818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT04724577

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
Study: NCT02039973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-sharing approach to group therapy
Description: Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard of care
Study: NCT02209805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02768441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Description: Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
Study: NCT02346110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-adrenaline
Description: 50 mg bupivacaine and 50 μg adrenalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-adrenaline
Description: 50 mg bupivacaine and 50 μg adrenalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 1 mL of sodium chloride solution as placebo
Study: NCT01844206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Morphine
Description: Patients will be given 3mg epidural morphine, 24 hours after the initial dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural Saline
Description: Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
Study: NCT04319081

Intervention type: DRUG
Intervention: PCSK9 inhibitor
Description: Patients are included after PCSK9 inhibitors prescription , at the first dispensation
Study: NCT03170466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Palliative Care
Description: The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
Study: NCT03179293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
Study: NCT02919267

Intervention type: DEVICE
Group type: OTHER
Intervention: Double lumen tube
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.

Intervention type: DEVICE
Group type: OTHER
Intervention: Double lumen tube
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchial blocker
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchial blocker
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
Study: NCT03635385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis technics
Description: Blood draw will be performed for anti bodies dosages

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis technics
Description: Blood draw will be performed for anti bodies dosages
Study: NCT01668953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needle Fenestration
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected.
Study: NCT02160847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DRIVE Program
Description: The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
Study: NCT00688311

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Description: A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02719353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Extended Range test lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A Extended Range test lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A control lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A control lens
Description: contact lens
Study: NCT03340233

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI (cardiac) off-label use gadolinium contrast (IND exempt)
Description: Clinical MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI (cardiac)
Description: MRI without contrast

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI (cardiac)
Description: MRI without contrast
Study: NCT02947256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard laparoscopic cholecystectomy
Description: which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RI approach
Description: which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
Study: NCT02134899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors maintenance
Description: Usual treatment
Study: NCT04481035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
Study: NCT04501783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: TL-FVP-t will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard concomitant therapy
Description: Standard of care according to MoH of Russian Federation recomendation for COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard concomitant therapy
Description: Standard of care according to MoH of Russian Federation recomendation for COVID-19
Study: NCT03966937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
Study: NCT03285503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
Study: NCT02763397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBM-DBS
Description: DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS
Description: DBS will be switched off
Study: NCT03524352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fecal microbiota
Description: fecal microbiota in suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile saline
Study: NCT04972370

Intervention type: OTHER
Intervention: Patients with Unilateral Cleft Lip with or without Cleft Palate
Description: 2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
Study: NCT03785613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product T1: Buprenorphine patch (9 mg)
Description: Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product T2: Buprenorphine patch (3.8 mg)
Description: Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product R: Transtec patch (20 mg)
Description: Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo patch to T1
Description: Placebo patch to T1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo patch to T2
Description: Placebo patch to T2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo patch to R
Description: Placebo patch to R.
Study: NCT01421797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortrosyn
Description: single IV bolus of 0.25 mg will be administered
Study: NCT05153642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microsurgical intervention
Description: The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
Study: NCT03762928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
Study: NCT02557906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast reconstruction - implant and an ADM (SurgiMend)
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reconstruction- autologous tissue
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reconstruction- implant + dermal sling/LD flap
Description: Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
Study: NCT01634958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Phleum
Description: Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Phleum
Description: Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Phleum
Description: Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Phleum
Description: Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
Study: NCT01394250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Cold, Vibrational Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Lidocaine 4% Cream
Description: Applied to anticipated IV site at least 30 minutes prior to cannulation.
Study: NCT01614847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tears
Description: At random, subjects will receive isotonic artificial tear or a control (normal saline).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: At random, subjects will receive isotonic artificial tear or a control (normal saline).